Manufacturer record
Supermax Drugs & Pharmaceuticals Pvt. Ltd.(Unit-II): regulatory record
Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
3 batches manufactured by Supermax Drugs & Pharmaceuticals Pvt. Ltd.(Unit-II) (Uttarakhand) were declared Not of Standard Quality between December 2022 and April 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Records by type
3 records linked to Supermax Drugs & Pharmaceuticals Pvt. Ltd.(Unit-II) in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Sodium Bicarbonate Enteric Coated Tablets 500 mg | STG-250674Mfg 2025-01 · Exp 2027-01 | The sample does not confirm to claim as per Patent & Proprietory in respect to the Disintegration Test.Disintegration | DTL BaddiState lab | Apr 2026 |
| Mesalamine Prolonged Release Tablets IP | STG-251667Mfg 2025-08 · Exp 2027-07 | The sample does not conform to claim as per IP 2022 and in respect to the Test of Dissolution (3 Hours), Dissolution ( 8 Hours)Dissolution | RDTL, ChandigarhCDSCO lab | Feb 2026 |
| Decmax 4 mg (Dexmethasone Tablets IP 4 mg) | ST-21286Mfg 2021-06 · Exp 2024-05 | Related substances.Related substances | CDTL MumbaiCDSCO lab | Dec 2022 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.